Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 1 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Classical hematology 1

Conditions

Venous Thromboembolism 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Fondaparinux × Clear all
NCT00659399 2015-03-18

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NYU Langone Health

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT00476216 2014-03-05

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

University of Alabama at Birmingham

Phase 1 Completed
23 enrolled
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡